文献速递前列腺癌

穿刺活检检出Gleason 5模式与高危前列腺癌复发、转移及死亡相关

Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.
PubMed 文献 · J Urol · 2017-07-11

在SEARCH队列634例活检Gleason 8-10且行根治性前列腺切除术的高危前列腺癌男性中,按活检Gleason 4+4(394例,62%)与任何Gleason 5模式(240例,38%)分组。多变量分析显示,Gleason 5模式组相比Gleason 4+4组,生化复发风险无显著差异(HR 1.26,95%CI 0.99-1.61,p=0.065),但转移(HR 2.55,95%CI 1.50-4.35,p=0.001)、前列腺癌特异性死亡(HR 2.67,95%CI 0.1.26-5.66,p=0.010)和总死亡(HR 1.60,95%CI 1.09-2.34,p=0.016)风险显著更高。作者结论认为,术前按活检Gleason分级(4+4 vs 任何Gleason 5模式)对高危前列腺癌进行亚分类,可识别进展风险最高的男性;将所有Gleason 8-10肿瘤统一归为高危病变可能无法充分分层出预后最差的高危男性。

要点

  • 高危前列腺癌中活检Gleason 5模式者转移风险显著高于Gleason 4+4者(HR 2.55)。
  • 活检Gleason 5模式者前列腺癌特异性死亡风险显著高于Gleason 4+4者(HR 2.67)。
  • 活检Gleason 5模式者总死亡风险显著高于Gleason 4+4者(HR 1.60)。

核心结论

  • 术前按活检Gleason分级(4+4 vs 任何Gleason 5模式)对高危前列腺癌进行亚分类,可识别进展风险最高的男性。
  • 活检中任何Gleason 5模式与更高的转移、前列腺癌特异性死亡和总死亡风险相关。
  • 将所有Gleason 8-10肿瘤统一归为高危病变可能无法充分分层出预后最差的高危男性。

研究设计与样本

  • SEARCH(Shared Equal Access Regional Cancer Hospital)队列研究,纳入活检Gleason评分8-10且接受根治性前列腺切除术的高危前列腺癌男性。
  • 共634例高危男性,其中394例(62%)为Gleason 4+4,240例(38%)活检存在Gleason 5模式。
  • 比较Gleason 4+4组与任何Gleason 5模式组(即Gleason 3+5、5+3、4+5、5+4或5+5)。
  • 采用Kaplan-Meier法、log rank检验和Cox比例风险模型分析生化复发、转移、前列腺癌特异性生存和总生存的预测因素。

主要发现

  • 两组基线特征无显著差异。
  • 多变量分析中,相比Gleason 4+4组,Gleason 5模式组生化复发风险无显著差异(HR 1.26,95%CI 0.99-1.61,p=0.065)。
  • Gleason 5模式组转移风险显著高于Gleason 4+4组(HR 2.55,95%CI 1.50-4.35,p=0.001)。
  • Gleason 5模式组前列腺癌特异性死亡风险显著高于Gleason 4+4组(HR 2.67,95%CI 0.1.26-5.66,p=0.010)。
  • Gleason 5模式组总死亡风险显著高于Gleason 4+4组(HR 1.60,95%CI 1.09-2.34,p=0.016)。

关键数值与推荐

  • 高危前列腺癌定义为活检Gleason评分8-10。
  • Gleason 5模式组定义为活检存在任何Gleason 5模式(Gleason 3+5、5+3、4+5、5+4或5+5)。
  • 生化复发:Gleason 5模式组 vs Gleason 4+4组 HR 1.26(95%CI 0.99-1.61,p=0.065),无显著差异。
  • 转移:Gleason 5模式组 vs Gleason 4+4组 HR 2.55(95%CI 1.50-4.35,p=0.001)。
  • 前列腺癌特异性死亡:Gleason 5模式组 vs Gleason 4+4组 HR 2.67(95%CI 0.1.26-5.66,p=0.010);总死亡:HR 1.60(95%CI 1.09-2.34,p=0.016)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论认为,术前按活检Gleason分级(4+4 vs 任何Gleason 5模式)对高危前列腺癌进行亚分类,可识别进展风险最高的男性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the relative risk of biochemical recurrence, metastasis and death from prostate cancer contributed by biopsy Gleason pattern 5 among men at high risk with Gleason 8-10 disease in the SEARCH (Shared Equal Access Regional Cancer Hospital) cohort. MATERIALS AND METHODS: Men with biopsy Gleason sum 8-10 prostate cancer treated with radical prostatectomy were evaluated. The cohort was divided into men with Gleason 4 + 4 vs those with any pattern 5 (ie Gleason 3 + 5, 5 + 3, 4 + 5, 5 + 4 or 5 + 5). Predictors of biochemical recurrence, metastases, and prostate cancer specific and overall survival were analyzed using Kaplan-Meier, log rank test and Cox proportional hazards models. RESULTS: We identified 634 men at high risk in the SEARCH database, of whom 394 (62%) had Gleason 4 + 4 and 240 (38%) had Gleason pattern 5 on biopsy. Baseline characteristics did not significantly differ between the groups. On multivariable analysis relative to Gleason 4 + 4 men at high risk with Gleason pattern 5 showed no difference in the risk of biochemical recurrence (HR 1.26, 95% CI 0.99-1.61, p = 0.065). However, they were at significantly greater risk for metastasis (HR 2.55, 95% CI 1.50-4.35, p = 0.001), prostate cancer specific mortality (HR 2.67, 95% CI 0.1.26-5.66, p = 0.010) and overall mortality (HR 1.60, 95% CI 1.09-2.34, p = 0.016). CONCLUSIONS: Preoperative subclassification of high risk prostate cancer by biopsy Gleason grade (4 + 4 vs any Gleason pattern 5) identified men at highest risk for progression. Any Gleason 5 on biopsy is associated with a greater risk of metastasis, and prostate cancer specific and overall mortality. Grouping all Gleason 8-10 tumors together as high risk lesions may fail to fully stratify men at highest risk for poor outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stroup SP, Moreira DM, Chen Z, et al. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. J Urol. 2017. PMID: 28709888. doi:10.1016/j.juro.2017.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。